Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 5 of 5 results for saxenda

  1. Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) (TA749)

    NICE is unable to make a recommendation on liraglutide (Saxenda) for managing obesity in people aged 12 to 17 years because Novo Nordisk did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    1 December 2021

    Sections for TA749

  2. Liraglutide for managing overweight and obesity (TA664)

    Evidence-based recommendations on liraglutide (Saxenda) for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults.

    Technology appraisal guidance
    Published
    9 December 2020
    View recommendations

    Sections for TA664

  3. Obese, overweight with risk factors: liraglutide (Saxenda) (ES14)

    This evidence summary has been updated and replaced by NICE technology appraisal guidance 664.

    Evidence summary
    Published
    27 June 2017

  4. Digital services to enable easier access to weight management support

    Four digital programmes can be used to help the NHS deliver specialist weight management services to support the use of medication in England, NICE has said in draft guidance.

    News
    Published
    15 August 2023

  5. NICE recommends new treatment option for adults with obesity and non-diabetic hyperglycaemia who have a high risk of cardiovascular disease

    All eligibility criteria must be met for Liraglutide to be offered

    News
    Published
    30 October 2020